Management of Ardhavabhedaka (Migraine) associated with gastric disturbances with Godanti Mishrana and Kamadudha Rasa

Efficacy of Godanti Mishrana and Kamadudha Rasa in the management of Ardhavabhedaka (migraine) associated with gastric disturbances- A single arm open labelled clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/03/041418

Enrollment

Registered

2022-03-28

Start date

Unknown

Completion date

Unknown

Last updated

2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G439- Migraine, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patients having any of the classical signs and symptoms of Ardhavbhedaka (migraine) associated with gastric disturbances as mentioned in the diagnostic criteria Age group - 18 years to 65 years Uncomplicated cases of migraine Patients willing to participate in trial

Exclusion criteria

Exclusion criteria: Age below 18 years and above 65 years Pregnant and lactating women Patients having complications like tension headache or any other form of headache other than gastro intestinal migraine Patients suffering from secondary headaches like meningitis, brain tumour, encephalitis, cervical spondylitis etc and also headache due to refractive errors & glaucoma Patients suffering from malignant and accelerated hypertension, coronary artery disease, uncontrolled diabetes Patients suffering from any kind of malignancy, HIV and any other chronic disease Patient undergoing regular treatment for any other severe illness

Design outcomes

Primary

Measure	Time frame
It is expected that the trial drugs will break the pathogenesis of gastro intestinal migraine and thus will be effective in the management of Ardhavbhedaka (migraine) associated with gastric disturbancesTimepoint: on 0 days and after 2 months (8 weeks)	—

Secondary

Measure	Time frame
The drug will improve the quality of life and thus will act as disease modifying agent for Ardhavbhedaka (migraine) associated with gastric disturbancesTimepoint: on 0 days and after 2 months( 8 weeks)	—

Countries

India

Contacts

Public ContactDr Mandip Goyal

Institute of Teaching and Research n Ayurveda

mandipgoyal@ayurveduniversity.com9427572306

Outcome results